comparemela.com

Latest Breaking News On - Nivolumab combined with cabozantinib compared - Page 1 : comparemela.com

Ipsen Pharma: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma

Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cabometyx® and nivolumab shows durable survival benefits

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.